Leadership Overview
Tilray has 5 executives leading key functions including strategy, finance, information technology, administration, and Canadian operations.
Driven by innovation, Tilray is dedicated to advancing the cannabis industry through rigorous research, cultivation, and distribution of high-quality medical cannabis products, aiming to improve patient lives globally.
Driven by innovation, Tilray is dedicated to advancing the cannabis industry through rigorous research, cultivation, and distribution of high-quality medical cannabis products, aiming to improve patient lives globally.
Leadership Roles at Tilray
Irwin Simon - Chairman & Chief Executive Officer
Irwin Simon, the Chairman & Chief Executive Officer at Tilray, directs the overarching corporate strategy and operational execution for the company's global cannabis operations. Simon guides the integration of cultivation, production, and distribution channels, ensuring alignment with Tilray's mission to advance medical cannabis research and patient access. Overseeing all executive functions, the Chairman & Chief Executive Officer drives market expansion initiatives and fosters key stakeholder relationships. This leadership role involves setting the strategic vision for product development and regulatory compliance across all operating regions. By championing innovation in cannabinoid science, Irwin Simon ensures Tilray maintains its position as a leader in the pharmaceutical manufacturing sector. Ultimately, Simon secures the company's long-term growth and financial stability through decisive leadership and strategic foresight.

Carl Merton - Chief Financial Officer
Carl Merton, the Chief Financial Officer at Tilray, manages all financial planning, reporting, and capital allocation strategies. Merton oversees the company's fiscal health, ensuring robust financial controls and driving profitability across its diverse business units. Directing the finance department, the Chief Financial Officer analyzes market trends and economic conditions to inform investment decisions and optimize resource deployment. This critical role involves managing investor relations and securing funding to support Tilray's ambitious growth objectives in the pharmaceutical manufacturing space. By implementing rigorous budgeting processes and financial forecasting, Carl Merton ensures operational efficiency and sustainable revenue generation. Ultimately, Merton provides the financial stewardship necessary for Tilray's continued expansion and market leadership.
Blair MacNeil - President, Canada
Blair MacNeil, the President, Canada at Tilray, spearheads all strategic initiatives and operational oversight within the Canadian market. MacNeil directs the cultivation, production, and distribution of medical cannabis products across Canada, ensuring adherence to stringent quality and regulatory standards. Leading the Canadian division, the President, Canada drives market penetration and expands Tilray's footprint in this key region. This vital role involves managing relationships with Canadian healthcare providers and navigating the specific regulatory landscape of the Canadian pharmaceutical sector. By optimizing Canadian operations, Blair MacNeil ensures Tilray effectively serves patients and contributes to the advancement of cannabis-based therapies. Ultimately, MacNeil is instrumental in solidifying Tilray's leadership position within the Canadian medical cannabis industry.
Lloyd Brathwaite - Chief Information Officer
Lloyd Brathwaite, the Chief Information Officer at Tilray, architects and executes the company's comprehensive information technology strategy. Brathwaite oversees the development and maintenance of robust digital infrastructure, ensuring data security and operational efficiency across all global platforms. Leading the IT division, the Chief Information Officer drives technological innovation to support Tilray's research, cultivation, and distribution efforts in the medical cannabis sector. This position involves managing enterprise systems, cybersecurity protocols, and digital transformation initiatives to enhance productivity and compliance. By leveraging advanced technological solutions, Lloyd Brathwaite enables seamless data flow and supports the company's commitment to quality and patient care. Ultimately, Brathwaite ensures Tilray's technological capabilities are optimized to meet evolving market demands and regulatory requirements.
Roger Savell - Chief Administrative Officer
Roger Savell, the Chief Administrative Officer at Tilray, directs all non-operational corporate functions, ensuring seamless organizational efficiency. Savell oversees human resources, legal affairs, and corporate governance, establishing policies that support Tilray's mission and values. Managing the administrative infrastructure, the Chief Administrative Officer optimizes internal processes and fosters a productive work environment across all global sites. This key role involves ensuring compliance with all relevant regulations and managing corporate communications to maintain transparency and stakeholder trust. By streamlining administrative operations, Roger Savell enables the company to focus on its core competencies in medical cannabis research and distribution. Ultimately, Savell provides the essential support structure that underpins Tilray's strategic objectives and operational success.
Explore Leadership Teams in Manufacturing
Sanofi is a global biopharmaceutical company dedicated to improving lives through scientific innovation. The company focuses on discovering, developing, and delivering medicines and vaccines across immunology, rare diseases, neurology, oncology, and preventive care. Guided by research and patient needs, it works with healthcare partners worldwide to advance sustainable and responsible healthcare solutions.
Company Leadership IH
KN
AA
WS
Sun Pharma is a specialty generic pharmaceutical company that manufactures and distributes pharmaceutical formulations and active pharmaceutical ingredients. It is heaquartered in Mumbia, India.
Company Leadership LK
FN
KS
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in Phase III clinical trials to treat glabellar (frown) lines, as well as in Phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark,...
Company Leadership
MA
NC
Tolmar Pharmaceuticals is a fully integrated pharmaceutical company focused on the innovative development, manufacturing, and commercialization of specialty pharmaceuticals across multiple therapeutic areas, including Urology. Tolmar global headquarters, product development and manufacturing facilities are based in Northern Colorado, while North America commercial headquarters is based in Buffalo Grove, Illinois.
Company Leadership AD
JL
AC